Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 Dec 1;6(38):41350-9.
doi: 10.18632/oncotarget.5534.

The prognostic value of peripheral CD4+CD25+ T lymphocytes among early stage and triple negative breast cancer patients receiving dendritic cells-cytokine induced killer cells infusion

Affiliations

The prognostic value of peripheral CD4+CD25+ T lymphocytes among early stage and triple negative breast cancer patients receiving dendritic cells-cytokine induced killer cells infusion

Qing-Kun Song et al. Oncotarget. .

Abstract

Objective: This study aimed to assess the prognostic value of CD4+CD25+ T lymphocyte in peripheral blood among breast cancer patients treated with adoptive T lymphocytes immunotherapy.

Methods: 217 patients participated in the follow-up study. CD4+CD25+ proportion was measured by flow cytometry in peripheral T cells. The median survival was estimated by Kaplan-Meier curve, Log-rank test and Cox hazard proportion regression model, between groups of CD4+CD25+ proportion more than 5% and less than or equal to 5% in peripheral T cells.

Results: Peripheral CD4+CD25+ T lymphocytes had not a relationship with progression-free survival. It was featured that above 5% peripheral CD4+CD25+ proportion of T cells was related with the median overall survival by a shorten of 51 months (p < 0.05) with the HR 1.65 (95%CI 1.04, 2.62). Above 5% CD4+CD25+proportion of T cells produced the HR to be 1.76 (95%CI 1.07, 2.87) In stage 0-II patients, and 3.59 (95%CI 1.05, 12.29) in triple negative breast cancer patients.

Conclusions: Cellular immunity restoration recovered by adoptive T cell infusions which resulted in less proportion of peripheral CD4+CD25+T lymphocytes could be a potential prognostic indicator among early stage and triple negative patients.

Keywords: CD4+CD25+ T lymphocyte; adoptive cell therapy; early stage breast cancer; prognosis; triple negative breast cancer.

PubMed Disclaimer

Conflict of interest statement

CONFLICTS OF INTEREST

There are none.

Figures

Figure 1
Figure 1. Effects of CD4+ CD25+ proportion of T cells on survival with 95%CI among BC patients, a. progression-free survival, b. overall survival
Figure 2
Figure 2. Effect of CD4+CD25+proportion of T cells on overall survival with 95%CI among BC patients in stage ≤ II
Figure 3
Figure 3. Effect of CD4+CD25+proportion of T cells on overall survival with 95%CI among TNBC patients

Similar articles

Cited by

References

    1. Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin D, Forman D, Bray F. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Internet] Lyon, France: International Agency for Research on Cancer; 2013. Available from: http://globocan.iarc.fr, accessed on 26/01/2015.
    1. Song Q, Wang X, Zhou X, Yang H, Li Y, Wu J, Ren J, Lyerly HK. Breast Cancer Challenges and Screening in China: Lessons from Current Registry Data and Population Screening Studies. The Oncologist. 2015;20:1–7. - PMC - PubMed
    1. Jiang Y, Li Y, Zhu B. T-cell exhaustion in the tumor microenvironment. Cell death & disease. 2015;6:e1792. - PMC - PubMed
    1. Choudhury A, Palma M, Mellstedt H. The future of cancer vaccines for non-small-cell lung cancer: ongoing trials. Clinical lung cancer. 2008;1:S37–44. - PubMed
    1. Joshi PS, Liu JQ, Wang Y, Chang X, Richards J, Assarsson E, Shi FD, Ljunggren HG, Bai XF. Cytokine-induced killer T cells kill immature dendritic cells by TCR-independent and perforin-dependent mechanisms. Journal of leukocyte biology. 2006;80:1345–1353. - PubMed

Publication types

MeSH terms

Substances